Breadcrumbs

South Australian Medicines Evaluation Panel (SAMEP)

The South Australian Medicines Evaluation Panel (SAMEP) was established in 2011 as an expert standing committee of the South Australian Medicines Advisory Committee (SAMAC) to ensure that all public hospitals provide a consistent approach to the management of High Cost Medicines. The main role of SAMEP is to review the use of High Cost Medicines, for a list of medicines being reviewed or previously reviewed, see the High Cost Medicine reviews page. 

SAMEP were the winners of the 2014 SA Health Award "Excellence in Non-clinical Services"

Their role

The role of SAMEP includes:

  • Evaluating the safety, the clinical efficacy and cost-effectiveness of high cost medicines proposed for inclusion in the Statewide High Cost Medicines Formulary.
  • Initiating reviews to evaluate the safety and effectiveness of high cost medicines which are not registered for use within Australia for the purpose of providing guidance to local hospital drug committees with regards to consideration of individual patient use requests.
  • Making recommendations to SAMAC with regards to which high cost medicines should be made available in South Australian public hospitals and on the potential place in therapy of these medicines.
  • Facilitating the monitoring of high cost medicine use in South Australian public hospitals.

Meeting dates

SAMEP meet every two months to review high cost medicine formulary applications. Scheduled meetings for 2018 are:

  • 31 January
  • 21 March
  • 23 May
  • 18 July
  • 19 September
  • 21 November

Membership

Chaired by Associate Professor Catherine Hill, SAMEP includes specialist clinicians, pharmacists, health economists, an ethicist and a consumer representative.

See below for a full listing of members.

Contact

All enquiries regarding the High Cost Medicines policy or SAMEP should be directed to the Executive Officer to SAMEP at SAMEP@sa.gov.au.

Membership


Name Expertise

Professor Catherine Hill, Chair

Staff Specialist Rheumatology Unit, The Queen Elizabeth and Royal Adelaide Hospitals

Dr Damian Clark

Paediatric Neurologist, Women's and Children's Hospital

Dr Chris Pearson

General Medicine, Women's and Children's Hospital

Dr Ganessan Kichenadasse

Consultant, Medical Oncology, Flinders Medical Centre

Dr Sudarsha  Selva-Nayagam

Director Medical Oncology, Royal Adelaide Hospital

Dr Michael Ward

Lecturer, School of Pharmacy and Medical Sciences, University of South Australia

Ms Joy Gailer

Clinical Pharmacist, Drug and Therapeutics Information Service, Repatriation General Hospital

Ms Catherine Booth

Clinical Pharmacist, Women's and Children's Hospital

Ms Kirsty Scarborough

Senior Pharmacist, Royal Adelaide Hospital

Professor Tracy Merlin

Manager, Adelaide Health technology Assessment, University of Adelaide

Dr Jennie Louise

Senior Statistician and ethicist, Adelaide Health Technology Assessment

Dr Benjamin Reddi

Staff Specialist, Intensive Care Unit, Royal Adelaide Hospital

Ms Naomi Burgess

Director, Medicines & Technology Programs, SA Health (ex officio)

Dr Pravin Hissaria

Clinical Immunologist and Immunopathologist, Royal Adelaide Hospital

Ms Anne Mussared

Consumer representative, Health Consumers Alliance, South Australia

Ms Camille Schubert

Health Economist, Adelaide Health technology Assessment, University of Adelaide

Dr Rami Tadros

Department of Clinical Pharmacology, The Royal Adelaide Hospital, South Australia

Dr David Ross

Department of Haematology and Bone Marrow Transplantation, The Royal Adelaide Hospital

Ms Robyn Lambert

SAMEP Executive Officer (ex officio)

 

^ Back to top